Smiths Medical Offers Innovative Technology that Reduces the Need for Occlusion De-clotting Medication The Nexus TKO^® anti-reflux technology is clinically proven to decrease occlusions in central venous catheters by 58%^1 Business Wire ST. PAUL, Minn. -- May 14, 2013 Smiths Medical, a leading global medical device manufacturer, announced today that there is an alternative product that decreases catheter occlusions, a common problem with IV catheters. Smiths Medical distributes Nexus TKO^® (To Keep Open) needleless connectors, a solution that can help healthcare facilities affected by the current supply constraint of the occlusion de-clotting medication Cathflo^® Activase^® (alteplase)^2. Nexus TKO^® needleless connectors contain an innovative pressure-activated anti-reflux technology that prolongs the life of central/peripheral IV lines. This unique anti-reflux capability helps prevent blood backing up into IV catheter tips and hubs from patient movement (coughing, sneezing, vomiting), syringe connection and disconnection, IV bags running dry, syringe plunger rebound and pressure from ventilators or other hospital equipment. The Nexus TKO^® needleless connector also has an important clear, rigid, straight fluid path, which allows a thorough and easy view of effective flush. “The Nexus TKO^® needleless connectors with anti-reflux technology, distributed by Smiths Medical, are proven to help maintain catheter patency and reduce the need for de-clotting medication,” said Jeff Brown, Vice President Sales & Marketing Smiths Medical, Americas Region. “With the current supply constraint of Cathflo^® Activase^® (alteplase) for catheter occlusions, we are pleased to offer customers a simple solution that requires no change to protocol.” Blood reflux is one of the most common unintended consequences in IV therapy^3. Blood reflux can provide an environment for microbes to create biofilm which can potentially lead to a catheter-related blood stream infection. Attaching the Nexus TKO^® needleless connector to IV catheters has proven to reduce peripherally inserted central catheter (PICC) and central line occlusion by 58%^1, increase peripheral catheter life by over 51%^1, and decrease peripheral catheter phlebitis and infiltrates by 60%^1. Reducing the risk of occlusions can result in a decrease in the need for occlusion de-clotting medication which is currently under a supply constraint. The Nexus TKO^® needleless connectors are manufactured by Nexus Medical, LLC and distributed by Smiths Medical in the U.S. and Canada. More product information can be found by contacting Smiths Medical at 1-800-258-5361 or visiting www.smiths-medical.com. 1.Jasinsky, RN, BSN, J. Wurster, RN, MSN, Occlusion Reduction and Heparin Elimination Trial using an Anti-Reflux Device on Peripheral and Central Intravenous Lines, Intravenous Nurses Society, January/February 2009: 33-39. 2.Zigulis, Carol. "Product Availability Information for Cathflo® Activase® (alteplase) 2mg, Activase® (alteplase) 50mg and Activase® (alteplase) 100mg." Letter. 25 March 2013. 3.Hadaway, RN, C, CRNI, Med, Reopening the Pipeline, Nursing 2005, Volume 35. About Smiths Medical Smiths Medical www.smiths-medical.com is a leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. It is part of Smiths Group www.smiths.com, a global leader in applying advanced technologies for markets in threat and contraband detection, energy, medical devices, communications and engineered components. Smiths Group employs around 22,000 people in more than 50 countries. Contact: Smiths Medical Judith Rossi, 781-792-2539 E-mail: email@example.com
Smiths Medical Offers Innovative Technology that Reduces the Need for Occlusion De-clotting Medication
Press spacebar to pause and continue. Press esc to stop.